Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LNCB74 · 1 trial · 6 indications
Incidence of AEs, SAEs, AEs meeting protocol defined DLT criteria, AEs leading to discontinuation and death, and laboratory abnormalities per NCI CTCAE v5.0
Maximum tolerated dose (MTD), maximum administered dose (MAD) and/or recommended Phase 2 dose (RP2D) of LNCB74
| Arm | Type | Description |
|---|---|---|
| Part 1 - Dose Escalation and Backfills | EXPERIMENTAL | Aim: Doses of LNCB74 will be escalated to determine the maximum tolerated dose (MTD), maximum administered dose (MAD) and/or recommended Phase 2 dose (RP2D). One or more dose levels will be backfilled for safety and additional biomarker data. |
| Part 2 - Dose Expansion / Optimization | EXPERIMENTAL | Aim: The objectives of the Part 2 Dose Expansion/Optimization are: i) to evaluate safety, tolerability, anti-tumor activity, and pharmacodynamics of LNCB74 in a more homogenous population and ii) characterize the minimally safe and effective dose in a particular tumor type and determine recommended Phase 2 dose(s) (RP2D). |
| Name | Type | Description |
|---|---|---|
| LNCB74 | DRUG | LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression. |
Inclusion Criteria: 1. The participant provides written informed consent 2. ≥ 18 years of age on day of signing informed consent. 3. Participant with histologically or cytologically confirmed diagnosis of advanced unresectable and/or metastatic solid tumors 4. A male participant must agree to use c...
Top 20 of 60 competitors
LNCB74 is an investigational small molecule being developed for the treatment of ovarian cancer. It is also being studied in other advanced or metastatic solid tumors, including breast cancer, endometrial cancer, biliary tract cancer, and non-small cell lung cancer. The drug is currently in Phase 1 clinical development.
LNCB74 targets B7-H4, a protein that is part of the B7 family of immune checkpoint molecules. By targeting B7-H4, the drug aims to modulate the immune response against tumors. This mechanism is being evaluated in a Phase 1 clinical trial for advanced solid tumors.
LNCB74 is being developed by NextCure, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol NXTC. NextCure is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of LNCB74 in patients with advanced solid tumors.
LNCB74 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is recruiting patients to evaluate the drug's safety, tolerability, and preliminary efficacy in advanced solid tumors.
LNCB74 is being studied in a Phase 1 clinical trial with the identifier NCT06774963. This trial is titled 'A Phase 1 Study of LNCB74 in Advanced Solid Tumors' and is currently recruiting participants in the United States. The trial aims to enroll 145 patients with various advanced solid tumors.
No, LNCB74 is not the same as B7-H4. LNCB74 is the drug candidate, while B7-H4 is the molecular target that the drug binds to. B7-H4 is a protein expressed on tumor cells, and LNCB74 is designed to interact with this target to potentially treat cancer.